{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:35:51Z","timestamp":1763141751852,"version":"3.41.2"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pheochromocytoma (PHEO) and paraganglioma (PGL) are relatively rare neuroendocrine tumors. The factors affecting patients with early death remain poorly defined. We aimed to study the demographic and clinicopathologic pattern and to develop and validate a prediction model for PHEO\/PGL patients with early death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data of 800 participants were collected from the Surveillance Epidemiology and End Results (SEER) database as a construction cohort, while data of 340 participants were selected as a validation cohort. Risk factors considered included the year of diagnosis, age at diagnosis, gender, marital status, race, insurance status, tumor type, primary location, laterality, the presence of distant metastasis. Univariate and multivariate logistic regressions were performed to determine the risk factors. R software was used to generate the nomogram. Calibration ability, discrimination ability, and decision curve analysis were analyzed in both construction and validation cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>PHEO and PGL patients accounted for 54.3% (N=434) and 45.7% (N=366), respectively. More than half of tumors (N=401, 50.1%) occurred in the adrenal gland, while 16.9% (N=135) were in aortic\/carotid bodies. For the entire cohort, the median overall survival (OS) was 116.0 (95% CI: 101.5-130.5) months. The multivariate analysis revealed that older age (<jats:italic>versus age younger than 31;<\/jats:italic> age between 31 and 60: OR=2.03, 95% CI: 1.03-4.03, <jats:italic>P=0.042<\/jats:italic>; age older than 60: OR=5.46, 95% CI: 2.68-11.12, <jats:italic>P&amp;lt;0.001<\/jats:italic>), female gender (<jats:italic>versus male gender;<\/jats:italic> OR=0.59, 95% CI: 0.41-0.87, <jats:italic>P=0.007<\/jats:italic>), tumor located in aortic\/carotid bodies (<jats:italic>versus tumor located in adrenal gland;<\/jats:italic> OR=0.49, 95% CI: 0.27-0.87, <jats:italic>P=0.015<\/jats:italic>) and the presence of distant metastasis (<jats:italic>versus without distant metastasis;<\/jats:italic> OR=4.80, 95% CI: 3.18-7.23, <jats:italic>P&amp;lt;0.001<\/jats:italic>) were independent risk factors of early death. The predictive nomogram included variables: age at diagnosis, gender, primary tumor location, and distant metastasis. The model had satisfactory discrimination and calibration performance: Harrell\u2019s C statistics of the prediction model were 0.733 in the construction cohort and 0.716 in the validation cohort. The calibration analysis showed acceptable coherence between predicted probabilities and observed probabilities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We developed and validated a predictive nomogram utilizing data from the SEER database with satisfactory discrimination and calibration capability which can be used for early death prediction for PHEO\/PGL patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.770958","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T05:38:51Z","timestamp":1645767531000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A Predictive Nomogram for Early Death in Pheochromocytoma and Paraganglioma"],"prefix":"10.3389","volume":"12","author":[{"given":"Huiyang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirellos Said","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basel","family":"Abdelazeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yile","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir P.","family":"Chekhonin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Peltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.14744\/semb.2020.18794","article-title":"Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings","volume":"54","author":"Aygun","year":"2020","journal-title":"SiSli Etfal Hastanesi Tip Bulteni \/ Med Bull Sisli Hosp"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2019.08.006","article-title":"Pheochromocytomas and Paragangliomas","volume":"48","author":"Tevosian","year":"2019","journal-title":"Endocrinol Metab Clinics North Am"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/mpa.0b013e3181ebb4f0","article-title":"The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors","volume":"39","author":"Chen","year":"2010","journal-title":"Pancreas"},{"key":"B5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1210\/er.2017-00062","article-title":"New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification","volume":"38","author":"Crona","year":"2017","journal-title":"Endocr Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2015.08.006","article-title":"Pheochromocytoma and Paraganglioma","volume":"25","author":"Kiernan","year":"2016","journal-title":"Surg Oncol Clinics North Am"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08220-3","article-title":"Update on Pheochromocytoma and Paraganglioma From the SSO Endocrine\/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma","volume":"27","author":"Patel","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical Risk Factors for Malignancy and Overall Survival in Patients With Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and Phaeochromocytoma: From Genetics to Personalized Medicine","volume":"11","author":"Favier","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020312","article-title":"Familial Malignant Catecholamine-Secreting Paraganglioma With Prolonged Survival Associated With Mutation in the Succinate Dehydrogenase B Gene","volume":"87","author":"Young","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.00829","article-title":"Malignant Pheochromocytoma: Current Status and Initiatives for Future Progress","volume":"11","author":"Eisenhofer","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10252","article-title":"National Cancer Data Base Report on Malignant Paragangliomas of the Head and Neck","volume":"94","author":"Lee","year":"2002","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/1758-3284-2-23","article-title":"Malignant Head and Neck Paragangliomas: Is There an Optimal Treatment Strategy","volume":"2","author":"Moskovic","year":"2010","journal-title":"Head Neck Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2013.03.010","article-title":"Malignant Head and Neck Paragangliomas: Treatment Efficacy and Prognostic Indicators","volume":"34","author":"Sethi","year":"2013","journal-title":"Am J Otolaryngol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23297","article-title":"Malignant Pheochromocytoma and Paraganglioma: A Population Level Analysis of Long-Term Survival Over Two Decades","volume":"107","author":"Goffredo","year":"2013","journal-title":"J Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1287681","article-title":"Normal Life Expectancy for Paraganglioma Patients: A 50-Year-Old Cohort Revisited","volume":"21","author":"de Flines","year":"2011","journal-title":"Skull Base"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01629-x","article-title":"Management and Outcome of Metastatic Pheochromocytomas\/Paragangliomas: A Monocentric Experience","volume":"45","author":"De Filpo","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1055\/a-0851-3275","article-title":"Prognostic Factors of Malignant Pheochromocytoma and Paraganglioma: A Combined SEER and TCGA Databases Review","volume":"51","author":"Mei","year":"2019","journal-title":"Horm Metab Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e924858","DOI":"10.12659\/MSM.924858","article-title":"Early Death Incidence and Prediction in Stage IV Breast Cancer","volume":"26","author":"Zhao","year":"2020","journal-title":"Med Sci Monit"},{"key":"B22","first-page":"1","article-title":"Health System Performance for the High-Need Patient: A Look at Access to Care and Patient Care Experiences","volume":"27","author":"Salzberg","year":"2016","journal-title":"Issue Brief (Commonw Fund)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7150\/jca.46152","article-title":"The Nomogram for Early Death in Patients With Bone and Soft Tissue Tumors","volume":"11","author":"Xu","year":"2020","journal-title":"J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.09138.x","article-title":"Predicting Individual Outcomes After Radical Cystectomy: An External Validation of Current Nomograms","volume":"106","author":"Zaak","year":"2010","journal-title":"BJU Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.11.005","article-title":"Nomogram Predicting Locoregional Recurrence to Assist Decision-Making of Postmastectomy Radiation Therapy in Patients With T1-2n1 Breast Cancer","volume":"103","author":"Luo","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-019-03306-1","article-title":"The Incidence, Associated Factors, and Predictive Nomogram for Early Death in Stage IV Colorectal Cancer","volume":"34","author":"Wang","year":"2019","journal-title":"Int J Colorectal Dis"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.770958\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T05:38:55Z","timestamp":1645767535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.770958\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":26,"alternative-id":["10.3389\/fonc.2022.770958"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.770958","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"article-number":"770958"}}